References
- Chen D, Kristensen D. Opportunities and challenges of
developing thermostable vaccines. Expert Rev Vaccines. 2009; 8(5):
547-557. PubMed | Google
Scholar
- Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling
J et al. Thermostable formulations of a hepatitis B
vaccine and a meningitis A polysaccharide conjugate
vaccine produced by a spray drying method.
Vaccine. 2010; 28(31): 5093-5099. PubMed | Google
Scholar
- Karp CL, Lans D, Esparza J, Edson EB, Owen KE, Wilson
CB, Heaton PM, Levine OS, Rao R. Evaluating the value
proposition for improving vaccine thermostability to increase vaccine
impact in low and
middle-income countries. Vaccine. 2015; 33(30): 3471-3479. PubMed | Google
Scholar
- Humphreys G. Vaccination: rattling the supply chain.
Bull World Health Organ. 2011; 89(5): 324-325. PubMed | Google
Scholar
- Zaffran M, Vandelaer J, Kristensen D, Melgaard B,
Yadav P, Antwi-Agyei KO, Lasher H. The imperative for
stronger vaccine supply and logistics systems. Vaccine.
2013; 31(Suppl 2): B73-B80. PubMed | Google
Scholar
- World Health Organization (WHO). Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: Guidance for immunization programme decision-makers and managers - WHO/IVB/13.04. 2013.Geneva. WHO. Accessed 12 February 2015.
- Lydon P, Zipursky S, Tevi-Benissan C, Djingarey
MH, Gbedonou P, Youssouf BO, et al. Economic benefits
of keeping vaccines at ambient temperature during mass
vaccination: the case of meningitis
A vaccine in Chad. Bull World Health Organ. 2014; 92(2):
86-92. PubMed | Google
Scholar
- Creese A, Parker D. WHO. Cost analysis in primary health care: A training manual for programme managers. 1994. Geneva. Accessed 12 February 2015.
- WHO. Immunization,
Vaccines and Biologicals. Immunization Planning and
Financing.
Accessed 12 February 2015.
- PATH. Cold
Chain Equipment Manager (CCEM). 2012.Seattle. PATH. Accessed 12
February 2015.
- WHO. Guidelines
for estimating costs of introducing new vaccines
into the national immunization system - WHO/V&B/02.11. 2002.Geneva.WHO.
Accessed 12 February 2015.
- Levin A, Levin C, Kristensen D, Matthias D. An
economic evaluation of thermostable vaccines in Cambodia,
Ghana and Bangladesh. Vaccine. 2007; 25(39-40): 6945-6957. PubMed | Google
Scholar
- Lee BY, Cakouros BE, Assi TM, Connor DL, Welling
J, Kone S, et al. The impact of making vaccines thermostable
in Niger’s
vaccine supply chain. Vaccine. 2012; 30(38): 5637-5643. PubMed | Google
Scholar
- Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff
TA, Widjaya A, Maynard JE. At-birth immunisation against
hepatitis B using a novel pre-filled immunisation device stored outside
the cold
chain. Vaccine. 1999; 18(5-6): 498-502. PubMed | Google
Scholar
- Davillou C. Cold chain costing: A study of the
costs associated with the yellow fever vaccination
campaign in Ghana. World Health Organization Working
Paper. April 2012. Unpublished.